Annexon/$ANNX
1D1W1MYTD1Y5YMAX
Capital at risk
About Annexon
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
- Ticker
- $ANNX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 92
- Headquarters
- Brisbane, United States
- Website
- www.annexonbio.com
Annexon Metrics
BasicAdvanced
$781M
-
-$1.13
1.21
-
Price and volume
Market cap
$781M
Beta
1.21
52-week high
$7.18
52-week low
$2.54
Average daily volume
3M
Financial strength
Current ratio
5.529
Quick ratio
5.437
Long term debt to equity
0.116
Total debt to equity
0.132
Profitability
EBITDA (TTM)
-208.388
Management effectiveness
Return on assets (TTM)
-51.54%
Return on equity (TTM)
-105.26%
Valuation
Price to book
3.87
Price to tangible book (TTM)
3.87
Price to free cash flow (TTM)
-3.834
Free cash flow yield (TTM)
-26.08%
Free cash flow per share (TTM)
-1.075
Growth
Earnings per share change (TTM)
-11.45%
3-year earnings per share growth (CAGR)
-17.01%
What the Analysts think about Annexon
Analyst ratings (Buy, Hold, Sell) for Annexon stock.
Analyst projections of the future price of Annexon stock.
Bulls say / Bears say
Tanruprubart showed rapid, clinically meaningful improvement in strength and disability in all ten initial US and European FORWARD patients. The result is consistent with Annexon’s earlier Phase 3 evidence and supports a planned US BLA filing in the fourth quarter of 2026, while the European application is already under review. (GlobeNewswire, GlobeNewswire)
The ARCHER II geographic atrophy trial enrolled 659 patients and is reporting strong execution, with discontinuation below 10% and treatment compliance above 95%. Its added Month 24 endpoint gives vonaprument another opportunity to demonstrate protection against vision loss beyond the Month 15 assessment. (GlobeNewswire, GlobeNewswire)
Annexon has bought time to reach its key clinical and regulatory catalysts. Cash, cash equivalents and short-term investments were $209.2 million at the end of June, while an Oxford Finance facility of up to $200 million is expected to fund operations and milestones into 2028. (GlobeNewswire, Last10K)
The geographic atrophy thesis still depends on an unreported Phase 3 result. If the Month 15 endpoint is not met, the key assessment may run to the Month 24 analysis, with full ARCHER II completion not expected until the third quarter of 2027. (GlobeNewswire, GlobeNewswire)
Annexon remains loss-making and cash-hungry while it funds late-stage trials and regulatory work. It reported a $99.5 million net loss and $94.8 million of operating cash use in the first half of 2026, leaving future financing needs if approvals or launch plans slip. (Last10K)
The encouraging Guillain-Barré evidence comes from only ten patients in an open-label FORWARD cohort, so it is not yet a robust test against a control group. The European application is still under review and the US filing is only planned for the fourth quarter of 2026, leaving meaningful clinical and regulatory risk. (GlobeNewswire, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 28 Sept 2026.
Annexon Financial Performance
Revenues and expenses
Annexon Earnings Performance
Company profitability
Upcoming events
No upcoming events
Annexon News
AllArticlesVideos
Funds containing Annexon
AllUSDGBPEUR
Fund name | Fund size | $ANNX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.